hellotayssir/FinQA_TAT-QA_financial_finetuning_dataset huggingface dataset:
Income Tax Provision Reconciliation
The difference between the income tax benefit (provision) and income taxes computed using the U.S. federal income tax rate was as follows for the years ended September 30, 2019, 2018, and 2017 (amounts shown in thousands):
Table:
 | 2019 | 2018 | 2017
Amount computed using statutory rate | $841 | $2,122 | $(1,078)
Net change in valuation allowance for net deferred tax assets | (459) | (367) | 10,058
AMT and other | — | (191) | 20
Foreign rate differential | 664 | 22 | (169)
Non-deductible items | (151) | (276) | (370)
State income tax | (370) | 50 | (34)
Impact of tax reform on deferred taxes | — | (4,901) | —
Research and development credits | 1,694 | 475 | 2,494
Foreign income tax | (494) | — | —
Stock compensation, net | 1,539 | — | —
Income tax benefit (provision) | $3,264 | $(3,066) | $10,921


Question: What is the sum of amount computed using statutory rate and foreign rate differential in 2018 as a percentage of 2019?
Answer: 1.42
Calculation: (2,122+22)/(841+664)
Section D: People
This section provides information about our employee benefit obligations, including annual leave, long service leave and post-employment benefits. It also includes details about our share plans and the compensation paid to Key Management Personnel.
15. EMPLOYEE BENEFITS.
1. Included within current provisions in the statement of financial position.
2. Included within non-current provisions in the statement of financial position.
Employee benefits liability
Employee benefits liability represents amounts provided for annual leave and long service leave. The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service.
Based on past experience, the Group does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled within the next 12 months. These amounts are presented as current liabilities since the Group does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.
Table:
 | 2019 | 2018
 | $’000 | $’000
Current employee benefits1 | 13,859 | 12,710
Non-current employee benefits2 | 189 | 675
Total employee benefits liability | 14,048 | 13,385


Question: What was the percentage change in current employee benefits in 2018 and 2019?
Answer: 9.04
Calculation: (13,859 - 12,710) / 12,710
Foreign Currencies
As a multinational business, the Company's transactions are denominated in a variety of currencies. When appropriate, the Company uses forward foreign currency contracts to reduce its overall exposure to the effects of currency fluctuations on its results of operations and cash flows. The Company's policy prohibits trading in currencies for which there are no underlying exposures and entering into trades for any currency to intentionally increase the underlying exposure.
The Company primarily hedges existing assets and liabilities associated with transactions currently on its balance sheet, which are undesignated hedges for accounting purposes.
As of December 31, 2019 and 2018, the Company had net outstanding foreign exchange contracts with net notional amounts of $183.3 million and $157.3 million, respectively. Such contracts were obtained through financial institutions and were scheduled to mature within one to three months from the time of purchase.
Management believes that these financial instruments should not subject the Company to increased risks from foreign exchange movements because gains and losses on these contracts should offset losses and gains on the underlying assets, liabilities and transactions to which they are related.
The following schedule summarizes the Company's net foreign exchange positions in U.S. dollars (in millions):
Amounts receivable or payable under the contracts are included in other current assets or accrued expenses in the accompanying Consolidated Balance Sheets. For the years ended December 31, 2019, 2018 and 2017, realized and unrealized foreign currency transactions totaled a loss of $5.0 million, $8.0 million and $6.3 million, respectively. The realized and unrealized foreign currency transactions are included in other income and expenses in the Company's Consolidated Statements of Operations and Comprehensive Income.
Table:
 |  | As of December 31, |  | 
 | 2019 |  | 2018 | 
 | Buy (Sell) | Notional Amount | Buy (Sell) |  Notional Amount
Japanese Yen | $49.8 | $49.8 | $29.9 | $29.9
Philippine Peso | 36.4 | 36.4 | 30.1 | 30.1
Malaysian Ringgit | 20.4 | 20.4 | — | —
Chinese Yuan | 20.2 | 20.2 | 20.4 | 20.4
Korean Won | 18.1 | 18.1 | 20.8 | 20.8
Czech Koruna | 11.9 | 11.9 | 9.2 | 9.2
Euro | — | — | 13.1 | 13.1
Other currencies - Buy | 21.9 | 21.9 | 26.3 | 26.3
Other currencies - Sell | (4.6) | 4.6 | (7.5) | 7.5
 | $174.1 | $183.3 | $142.3 | $157.3


Question: What was the net notional amount of net outstanding foreign exchange contracts as of December 31, 2018?
Answer: $157.3 million
Property and equipment consisted of the following:
Depreciation and amortization expense related to property and equipment was $86.5 million, $97.4 million and $88.8 million during 2019, 2018 and 2017, respectively.
Property and Equipment
Property and equipment is stated at cost. Depreciation is recorded over the shorter of the estimated useful life or the lease term of the applicable assets using the straight-line method beginning on the date an asset is placed in service. We regularly evaluate the estimated remaining useful lives of our property and equipment to determine whether events or changes in circumstances warrant a revision to the remaining period of depreciation. Maintenance and repairs are charged to expense as incurred.
Table:
 | Estimated Useful Lives | December 31, | 
 |  | 2019 | 2018
Computer equipment | 3 years | $ 434.8 | $ 417.6
Software | 3 years | 55.9 | 40.5
Land | Indefinite | 9.0 | 9.0
Buildings, including improvements | 5-40 years | 145.5 | 175.0
Leasehold improvements | Lesser of useful life or remaining lease term | 99.4 | 70.8
Other | 1-20 years | 25.7 | 27.0
Total property and equipment |  | 770.3 | 739.9
Less: accumulated depreciation and amortization |  | (511.7) | (440.9)
Property and equipment, net |  | $ 258.6 | $ 299.0


Question: What is the useful life of buildings, including improvements?
Answer: 5-40 years
Item 10. Directors, Executive Officers and Corporate Governance.
Executive Officers and Directors
The following sets forth certain information with respect to our executive officers and directors..
Garo H. Armen, PhD, Executive Chairman, is one of our founders and joined us in September 2004. Garo H. Armen is Chairman and Chief Executive Officer of Agenus
Inc., a biotechnology company he co-founded in 1994. From mid-2002 through 2004, he also served as Chairman of the Board of the biopharmaceutical company Elan
Corporation, plc, which he successfully restructured. Prior to Agenus Inc., Dr. Armen established Armen Partners, a money management firm specializing in biotechnology and
pharmaceutical companies and was the architect of the widely publicized creation of the Immunex Lederle oncology business in 1993. Earlier, he was a senior vice president of
research at Dean Witter Reynolds, having begun his career on Wall Street as an analyst and investment banker at EF Hutton. In 2002, Dr. Armen founded the Children of
Armenia Fund, a nonprofit organization dedicated to significantly rebuilding and revitalizing impoverished rural Armenian towns to provide immediate and sustainable benefits
to children and youth. He received the Ellis Island Medal of Honor in 2004 for his humanitarian efforts, and received the Sabin Humanitarian Award from the Sabin Vaccine
Institute in 2006 for his achievements in biotechnology and progressing medical research. Dr. Armen was also the Ernst & Young 2002 New York City Biotechnology
Entrepreneur of the Year, and received a Wings of Hope Award in 2005 from The Melanoma Research Foundation for his ongoing commitment to the melanoma community. Dr.
Armen received a PhD in physical chemistry from the Graduate Center, City University of New York, after which he worked as a research fellow at Brookhaven National
Laboratories in Long Island, NY. Dr. Armen brings to our Board a deep historical and practical knowledge of the business of the Company and its technologies, as well as
years of expertise in the financial and biopharmaceutical arenas.
Table:
Name | Age | Position (s)
Garo H. Armen | 67 | Executive Chairman of the Board of Directors
Alexander K. Arrow | 49 | Chief Financial Officer
Robert B. Stein | 69 | Director
Khalil Barrage | 55 | Director
Brian J. Corvese | 62 | Director
Josh Silverman | 49 | Director


Question: When did the Executive Chairman join the company?
Answer: September 2004
Fiscal 2019 Restructuring Plan
During Fiscal 2019, we began to implement restructuring activities to streamline our operations (Fiscal 2019 Restructuring Plan), including in connection with our recent acquisitions of Catalyst and Liaison, to take further steps to improve our operational efficiency. The Fiscal 2019 Restructuring Plan charges relate to workforce reductions and facility consolidations. These charges require management to make certain judgments and estimates regarding the amount and timing of restructuring charges or recoveries. Our estimated liability could change subsequent to its recognition, requiring adjustments to the expense and the liability recorded. On a quarterly basis, we conduct an evaluation of the related liabilities and expenses and revise our assumptions and estimates as appropriate.
As of June 30, 2019, we expect total costs to be incurred in conjunction with the Fiscal 2019 Restructuring Plan to be approximately $30.0 million, of which $28.3 million has already been recorded within "Special charges (recoveries)" to date. We do not expect to incur any further significant charges relating to this plan.
A reconciliation of the beginning and ending liability for the year ended June 30, 2019 is shown below.
Table:
Fiscal 2019 Restructuring Plan | Workplace reduction | Facility costs | Total
Balance payable as at June 30, 2018 | $— | $— | $—
Accruals and adjustments | 12,460 | 15,858 | 28,318
Cash payments | (10,420) | (4,739) | (15,159)
Non-cash adjustments | — | (3,393) | (3,393)
Foreign exchange | (221) | (2,438) | (2,659)
Balance payable as at June 30, 2019 | $1,819 | $5,288 | $7,107


Question: What is the difference between Balance payable as at June 30, 2019 for Workplace reduction & Facility costs?
Answer: -3469
Calculation: 1,819-5,288
Cubic Global Defense
Sales: CGD sales decreased 10% to $325.2 million in 2018 compared to $360.2 million in 2017. The year-over-year comparative sales and operating income were significantly impacted by an $8.0 million gain recognized on an equitable contract adjustment in fiscal 2017 for our littoral combat ship virtual training contract with the U.S. Navy. Sales were lower in fiscal 2018 on virtual training sales, air combat training system sales, and ground combat training system sales, while sales of international training support services increased between fiscal 2017 and 2018. The average exchange rates between the prevailing currency in our foreign operations and the U.S. dollar had no significant impact on CGD sales between 2017 and 2018.
Amortization of Purchased Intangibles: Amortization of purchased intangibles included in the CGD results amounted to $1.1 million in 2018 and $0.9 million in 2017.
Operating Income: CGD had operating income of $16.6 million in 2018 compared to $28.1 million in 2017. The decrease in operating income was primarily caused by the gain of $8.0 million recognized in fiscal 2017 due to the approval of a contract adjustment with the U.S. Navy described above. In fiscal 2018 an arbitrator awarded $1.7 million to a former reseller of our air combat training systems in the Far East, which was recorded as SG&A expense by CGD in 2018. In addition, CGD’s R&D expenditures increased approximately $1.8 million year-over-year. The increase in R&D expenditures is indicative of the acceleration of our development of next generation live, virtual, constructive, and game-based training systems. These decreases in operating income in fiscal 2018 were partially offset by increased operating income from ground combat training systems, which was higher primarily due to improvements in expected total costs for the development of two ground combat training system contracts in the Far East. The average exchange rates between the prevailing currency in our foreign operations and the U.S. dollar had no significant impact on CGD operating income between 2017 and 2018.
Adjusted EBITDA: CGD Adjusted EBITDA was $26.3 million in 2018 compared to $39.4 million in 2017. The decrease in Adjusted EBITDA was primarily driven by the same factors that drove the decrease in operating income described above excluding the increase in amortization which is excluded from Adjusted EBITDA.
Table:
 | Fiscal 2018 | Fiscal 2017 | % Change
 |  | (in millions) | 
Sales | $  325.2 | $  360.2 | (10)%
Operating income | 16.6 | 28.1 | (41)
Adjusted EBITDA | 26.3 | 39.4 | (33)


Question: For which years is the amortization of purchased intangibles included in the CGD results recorded?
Answer: 2018, 2017
Other Income/Expense
The following table details our other income/expenses for the years ended September 30, 2019 and 2018:
The decrease to other income (expenses) for the fiscal year ended September 30, 2019 as compared to the fiscal year ended September 30, 2018 was primarily driven by a decrease in Other income, net of $0.3 mil.
Table:
 | For the year ended |  | 
 | September 30, 2019 | September 30, 2018 | Increase (Decrease)
 | (Amounts in thousands) |  | 
Interest expense | $(99) | $(85) | $(14)
Interest income | 323 | 20 | 303
Foreign exchange gain (loss) | 157 | 263 | (106)
Other income, net | 3 | 297 | (294)
Total other income (expense), net | $384 | $495 | $(111)


Question: What is the company's net interest expense in 2018?
Answer: -65
Calculation: -$85 + 20
Director Compensation
In 2019, we compensated each non-management director of our Company by granting to each such outside director 15,000 RSUs. The RSUs vested in equal amounts of 3,750 RSUs on each of March 15, 2019, June 15, 2019, September 15, 2019 and December 15, 2019. In addition, we pay our non-management directors cash director fees of $40,000 per annum ($10,000 per quarter). Non-management directors also receive additional cash compensation on an annual basis for serving on the following Board committees: The Audit Committee Chairperson receives $7,500 and members receive $5,000; the Chairperson and members of each of the Compensation Committee and Nominating and Corporate Governance Committee receive annual fees of $3,750 and $2,500, respectively.
In consideration for serving as the sole member of our Strategic Development Committee, in June 2013 we issued to Niv Harizman a five-year stock option to purchase 300,000 shares of our common stock, at an exercise price of $1.88 per share, which option vested 100,000 shares on the date of grant, 100,000 shares on the first anniversary of the date of grant and vested 100,000 shares on the second anniversary from the grant date. On June 17, 2018, Mr. Harizman exercised the aforementioned stock option on a net (cashless) exercise basis by delivering to us 181,936 shares of our common stock and he received 118,064 shares of our common stock.
The following table sets forth the compensation awarded to, earned by or paid to all persons who served as members of our board of directors (other than our Named Executive Officers) during the year ended December 31, 2019. No director who is also a Named Executive Officer received any compensation for services as a director in 2019.
(1) Represents directors’ fees payable in cash to each non-management director of $10,000 per quarter ($40,000 per annum) for 2019 plus additional cash fees for serving on Board committees as disclosed in the text above.
(2) The amounts included in this column represent the grant date fair value of restricted stock unit awards (RSUs) granted to directors, computed in accordance with FASB ASC Topic 718. For a discussion of valuation assumptions see Note B[11] to our consolidated financial statements included in this Annual Report. The 15,000 RSUs granted to each non-management director vested on a quarterly basis beginning March 15, 2019. Each restricted stock unit represents the contingent right to receive one share of common stock.
(3) As of December 31, 2019, each of the above listed directors held outstanding stock options to purchase 35,000 shares of our common stock at an exercise price of $2.34 per share.
(4) Includes payment of dividends (dividend equivalent rights) on RSUs for 2019.
Table:
Name | Fees earned or paid in cash ($) (1) | Stock Awards ($) (2) (3) | All other compensation ($) (4) | Total ($)
Emanuel Pearlman | $ 50,000 | $ 39,000 | $ 750 | $  89,750
Niv Harizman | $ 46,250 | $ 39,000 | $ 750 | $  86,000
Alison Hoffman | $ 48,890 | $ 39,000 | $ 750 | $ 88,640


Question: What was the total amount of money received by one audit committee chairperson and one member?
Answer: 12500
Calculation: 7,500+5,000
The director compensation policies summarized above resulted in the following total compensation for our non-management directors in fiscal year 2019:
Director Compensation Table
(1) Oleg Khaykin, President and Chief Executive Officer, is not included in this table as he was an employee of the Company and as such received no compensation for his services as a director. His compensation is disclosed in the Summary Compensation Table.
(2) The amounts shown in this column represent the grant date fair values of RSUs issued pursuant to the Company’s 2003 Equity Incentive Plan, computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC Topic 718”), excluding the effect of estimated forfeitures. There can be no assurance that these grant date fair values will ever be realized by the non-employee directors. For information regarding the number of unvested RSUs held by each non-employee director as of the end of fiscal year 2019, see the column “Unvested Restricted Stock Units Outstanding” in the table below
Table:
DIRECTOR COMPENSATION |  |  | 
Name (1) | Fees Earned or Paid in Cash ($) | Stock Awards ($) (2) | Total ($)
Keith Barnes | 102,500 | 178,317 | 280,817
Richard E. Belluzzo | 160,000 | 178,317 | 338,317
Laura Black | 67,500 | 178,317 | 245,817
Tor Braham | 67,500 | 178,317 | 245,817
Timothy Campos | 77,500 | 178,317 | 255,817
Donald Colvin | 97,500 | 178,317 | 275,817
Masood A. Jabbar | 90,000 | 178,317 | 268,317


Question: How much did Keith Barnes earn in cash?
Answer: 102,500
jpmorgan chase & co./2016 annual report 35 five-year stock performance the following table and graph compare the five-year cumulative total return for jpmorgan chase & co . ( 201cjpmorgan chase 201d or the 201cfirm 201d ) common stock with the cumulative return of the s&p 500 index , the kbw bank index and the s&p financial index . the s&p 500 index is a commonly referenced united states of america ( 201cu.s . 201d ) equity benchmark consisting of leading companies from different economic sectors . the kbw bank index seeks to reflect the performance of banks and thrifts that are publicly traded in the u.s . and is composed of leading national money center and regional banks and thrifts . the s&p financial index is an index of financial companies , all of which are components of the s&p 500 . the firm is a component of all three industry indices . the following table and graph assume simultaneous investments of $ 100 on december 31 , 2011 , in jpmorgan chase common stock and in each of the above indices . the comparison assumes that all dividends are reinvested . december 31 , ( in dollars ) 2011 2012 2013 2014 2015 2016 .

Table:
december 31 ( in dollars ) | 2011 | 2012 | 2013 | 2014 | 2015 | 2016
jpmorgan chase | $ 100.00 | $ 136.18 | $ 186.17 | $ 204.57 | $ 221.68 | $ 298.31
kbw bank index | 100.00 | 133.03 | 183.26 | 200.42 | 201.40 | 258.82
s&p financial index | 100.00 | 128.75 | 174.57 | 201.06 | 197.92 | 242.94
s&p 500 index | 100.00 | 115.99 | 153.55 | 174.55 | 176.95 | 198.10
december 31 , ( in dollars ) .

Question: what was the 5 year return of the kbw bank index?
Answer: 158.82%
Calculation: subtract(258.82, const_100), divide(#0, const_100)
Revenue stream
The Company generates revenue primarily from the sales of equipment and sales of spares & service. The products and services described by nature in Note 1, can be part of all revenue streams.
The proceeds resulting from the patent litigation & arbitration settlements (€159 million) are included in the equipment revenue stream.
Table:
 | Year ended December 31, | 
(EUR thousand) | 2018 | 2019
Equipment revenue | 631,504 | 1,068,645
Spares & service revenue | 186,577 | 215,215
Total | 818,081 | 1,283,860


Question: What is the patent litigation & arbitration settlements expressed as a percentage of Equipment revenue in 2019?
Answer: 14.88
Calculation: 159 millions / 1,068,645 thousands
The following table summarizes the change in the valuation allowance (in thousands):
As of December 31, 2019, net operating loss (NOL) carryforwards for U.S. federal tax purposes totaled $31.4 million. Effective with the 2017 Tax Act in December 2017, NOLs generated after December 31, 2017, do not expire. Federal NOLs of $9.9 million expire at various dates from 2020 through 2037 and federal NOLs of $21.5 million do not expire. NOL carryforwards for state tax purposes totaled $40.6 million at December 31, 2019 and expire at various dates from 2020 through 2039.
Table:
Year Ended December 31 |  | 
 | 2019 | 2018
Vaulation allowances, beginning of year | $5,398 | $13,872
Net operating loss | 3,284 | 1,920
Expiration of net operating losses and limitations | (7) | (9,939)
Adjustment to deferred taxes | 29 | (321)
Impact of state tax rate change | 26 | (146)
Other adjusments | 9 | 12
Valuation allowance, end of year | $8,739 | $5,398


Question: What are the respective net operating loss in 2018 and 2019?
Answer: 1,920, 3,284
GasLog Ltd. and its Subsidiaries
Notes to the consolidated financial statements (Continued)
For the years ended December 31, 2017, 2018 and 2019
(All amounts expressed in thousands of U.S. Dollars, except share and per share data)
16. Voyage Expenses and Commissions
An analysis of voyage expenses and commissions is as follows:
Bunkers’ consumption and other voyage expenses represents mainly bunkers consumed during vessels’ unemployment and off-hire.
Table:
 |  | For the year ended December 31, | 
 | 2017 | 2018 | 2019
Brokers’ commissions on revenue | 6,456 | 7,555 | 7,527
Bunkers’ consumption and other voyage expenses | 8,948 | 12,819 | 16,245
Total | 15,404 | 20,374 | 23,772


Question: What was the change in bunkers’ consumption and other voyage expenses from 2018 to 2019?
Answer: 3426
Calculation: 16,245 - 12,819
If not presented separately in our income statement, restructuring expenses would have been classified in the different expense items in our income statement as follows:
Restructuring Expenses by Functional Area
Table:
€ millions | 2019 | 2018 | 2017
Cost of cloud and software | –138 | –3 | –55
Cost of services | –154 | –3 | –118
Research and development | –467 | –3 | –9
Sales and marketing | –299 | –11 | –2
General and administration | –71 | 0 | 2
Restructuring expenses | –1,130 | –19 | –182


Question: In which years are Restructuring Expenses by Functional Area calculated?
Answer: 2019, 2018, 2017